{"title_page": "Gamma-Amino-beta-hydroxybutyric acid", "text_new": "{{DISPLAYTITLE:''gamma''-Amino-''beta''-hydroxybutyric acid}}\n{{Drugbox\n| drug_name = \u03b3-Amino-\u03b2-hydroxybutyric acid\n| IUPAC_name = (\u00b1)-4-amino-3-hydroxybutanoic acid\n| image = GABOB.png\n| width = 225px\n| image2 = GABOB3d.png\n| width2 = 150px\n\n<!--Clinical data-->\n| tradename = Gamibetal, others\n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B / C / D / X -->\n| pregnancy_category = \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status = \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability = \n| protein_bound = \n| metabolism = \n| elimination_half-life = \n| excretion =\n\n<!--Identifiers-->\n| CAS_number = 924-49-2\n| CAS_supplemental = <br />352-21-6\n| UNII_Ref = {{fdacite|correct|FDA}}\n| UNII = 1ZHM019FLD\n| ATC_prefix = \n| ATC_suffix = \n| PubChem = 2149\n| ChEBI = 16080\n| ChEMBL = 93515\n| ChemSpiderID = 2064\n| DrugBank = \n| synonyms = Buxamine; Buxamina; Bussamina; \u03b3-Amino-\u03b2-hydroxybutyric acid; GABOB; \u03b2-Hydroxy-\u03b3-aminobutyric acid; \u03b2-Hydroxy-GABA\n\n<!--Chemical data-->\n| C=4 | H=9 | N=1 | O=3 \n| molecular_weight = 119.12 g/mol\n| SMILES = C(C(CN)O)C(=O)O\n| StdInChI_Ref = \n| StdInChI = 1S/C4H9NO3/c5-2-3(6)1-4(7)8/h3,6H,1-2,5H2,(H,7,8)\n| StdInChIKey_Ref = \n| StdInChIKey = YQGDEPYYFWUPGO-UHFFFAOYSA-N\n}}\n\n'''\u03b3-Amino-\u03b2-hydroxybutyric acid''' ('''GABOB'''), also known as '''\u03b2-hydroxy-\u03b3-aminobutyric acid''' ('''\u03b2-hydroxy-GABA'''), and sold under the brand name '''Gamibetal''' among others, is an [[anticonvulsant]] which is used for the treatment of [[epilepsy]] in [[Europe]], [[Japan]], and [[Mexico]].<ref name=\"IndexNominum2000\">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA44|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=44\u2013}}</ref><ref name=\"Smith2013\">{{cite book|author=Michael Bryant Smith|title=Methods of Non-\u03b1-Amino Acid Synthesis, Second Edition|url=https://books.google.com/books?id=pWxmAQAAQBAJ&pg=PA146|date=23 October 2013|publisher=CRC Press|isbn=978-1-4665-7789-3|pages=146\u2013}}</ref> It is a [[GABA analogue]], or an [[structural analog|analogue]] of the [[neurotransmitter]] [[\u03b3-aminobutyric acid]] (GABA), and has been found to be an [[endogenous]] [[metabolite]] of GABA.<ref name=\"Smith2013\" /><ref name=\"CooperBloom2003\">{{cite book|author1=Jack R. Cooper|author2=Floyd E. Bloom|author3=Robert H. Roth|title=The Biochemical Basis of Neuropharmacology|url=https://books.google.com/books?id=vNaM55VDoF8C&pg=PA112|year=2003|publisher=Oxford University Press|isbn=978-0-19-514007-1|pages=112\u2013}}</ref><ref name=\"MelisPaoletti2014\">{{cite journal|last1=Melis|first1=Gian B.|last2=Paoletti|first2=A. M.|last3=Mais|first3=V.|last4=Mastrapasqua|first4=N. M.|last5=Strigini|first5=F.|last6=Fruzzetti|first6=F.|last7=Guarnieri|first7=G.|last8=Gambacciani|first8=M.|last9=Fioretti|first9=P.|title=Dose-related effects of \u03b3-amino \u03b2-hydroxy butyric acid (GABOB) infusion on growth hormone secretion in normal women|journal=[[Journal of Endocrinological Investigation]]|volume=5|issue=2|year=2014|pages=101\u2013106|issn=0391-4097|doi=10.1007/BF03350499}}</ref><ref name=\"Hayashi1959\">{{cite journal|last1=Hayashi|first1=Takashi|title=The inhibitory action of \u03b2-hydroxy-\u03b3-aminobutyric acid upon the seizure following stimulation of the motor cortex of the dog|journal=The Journal of Physiology|volume=145|issue=3|year=1959|pages=570\u2013578|issn=0022-3751|doi=10.1113/jphysiol.1959.sp006163|pmid=13642322|pmc=1356963}}</ref>\n\n==Medical uses==\nGABOB is an anticonvulsant and is used in the treatment of [[epilepsy]].<ref name=\"IndexNominum2000\" /><ref name=\"Smith2013\" />\n\n==Pharmacology==\nGABOB is a [[GABA receptor agonist]].<ref name=\"Colombo2017\">{{cite book|author=Giancarlo Colombo|title=GABAB Receptor|url=https://books.google.com/books?id=ONHBDQAAQBAJ&pg=PA25|date=17 January 2017|publisher=Springer|isbn=978-3-319-46044-4|pages=25\u2013}}</ref> It has two [[stereoisomer]]s, and shows [[stereoselectivity]] in its actions.<ref name=\"Colombo2017\" /> Specifically, (''R'')-(\u2013)-GABOB is a moderate-[[potency (pharmacology)|potency]] [[agonist]] of the [[GABAB receptor|GABA<sub>B</sub> receptor]], while (''S'')-(+)-GABOB is a [[partial agonist]] of the GABA<sub>B</sub> receptor and an agonist of the [[GABAA receptor|GABA<sub>A</sub> receptor]].<ref name=\"Colombo2017\" /> (''S'')-(+)-GABOB is around twice as potent an anticonvulsant as (''R'')-(\u2013)-GABOB.<ref>{{ cite journal |vauthors=Roberts E, Krause DN, Wong E, Mori A | title = Different Efficacies of d- and l-\u03b3-Amino-\u03b2-Hydroxybutyric Acids in GABA Receptor and Transport Test Systems | journal = Journal of Neuroscience | year = 1981 | volume = 1 | issue = 2 | pages = 132\u2013140 | pmid = 6267220 | pmc = 6564147 | url = http://www.jneurosci.org/content/1/2/132.full.pdf | doi = 10.1523/JNEUROSCI.01-02-00132.1981 }}</ref> GABOB is used medically as a [[racemic mixture]].<ref name=\"Colombo2017\" />\n\nRelative to GABA, GABOB has more potent [[Neurotransmitter#Excitatory and inhibitory|inhibitory]] effects on the [[central nervous system]], perhaps due to its greater capacity to cross the [[blood\u2013brain barrier]].<ref name=\"Hayashi1959\" /><ref name=\"De MaioPasquariello1963\">{{cite journal|last1=De Maio|first1=D.|last2=Pasquariello|first2=G.|title=Gamma-amino-beta-hydroxybutyric acid (GABOB) and brain serotonin|journal=Psychopharmacologia|volume=5|issue=1|year=1963|pages=84\u201386|issn=0033-3158|doi=10.1007/BF00405577|pmid=14085623}}</ref> However, GABOB is of relatively low potency as an anticonvulsant when used by itself, and is more useful as an [[adjuvant]] treatment used alongside another anticonvulsant.<ref>{{ cite journal |vauthors=Chemello R, Giaretta D, Pellegrini A, Testa G |trans-title= Effect of \u03b3-amino-\u03b2-hydroxybutyric acid (GABHB) on experimentally-induced epileptic activity | language = Italian | journal = Rivista di Neurologia | year = 1980 | volume = 50 | issue = 4 | pages = 253\u2013268 | pmid = 7466221 | title=[Effect of gamma-amino-beta-hydroxybutyric acid (GABHB) on experimentally-induced epileptic activity]}}</ref><ref>{{ cite journal |vauthors=Garc\u00eda-Flores E, Far\u00edas R | title = \u03b3-Amino-\u03b2-hydroxybutyric acid as add-on therapy in adult patients with severe focal epilepsy | journal = Stereotactic and Functional Neurosurgery | year = 1997 | volume = 69 | issue = 1\u20134 Pt 2 | pages = 243\u20136| pmid = 9711762 | doi=10.1159/000099882}}</ref>\n\n==Chemistry==\nGABOB, or \u03b2-hydroxy-GABA, is a close [[structural analog]]ue of GABA (see [[GABA analogue]]), as well as of [[\u03b3-hydroxybutyric acid]] (GHB), [[phenibut]] (\u03b2-phenyl-GABA), [[baclofen]] (\u03b2-(4-chlorophenyl)-GABA),<ref name=\"pmid11830761\">{{cite journal | vauthors = Lapin I | title = Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug | journal = CNS Drug Rev | volume = 7 | issue = 4 | pages = 471\u201381 | year = 2001 | pmid = 11830761 | doi = 10.1111/j.1527-3458.2001.tb00211.x| url = | pmc = 6494145 }}</ref> and [[pregabalin]] (\u03b2-isobutyl-GABA).\n\n==Society and culture==\n\n===Generic name===\nGABOB has been referred to by the [[generic term|generic name]] ''buxamine'' or ''buxamina''.<ref name=\"IndexNominum2000\" /><ref name=\"Colombo2017\" />\n\n===Brand names===\nGABOB is sold primarily under the brand name Gamibetal.<ref name=\"IndexNominum2000\" /> It has also been marketed under a variety of other brand names including Aminoxan, Bogil, Diastal, Gabimex, Gabomade, Gaboril, Gamalate, and Kolpo.<ref name=\"IndexNominum2000\" /><ref name=\"Muller1998\">{{cite book|author=Muller|title=European Drug Index: European Drug Registrations, Fourth Edition|url=https://books.google.com/books?id=2HBPHmclMWIC&pg=PA181|date=19 June 1998|publisher=CRC Press|isbn=978-3-7692-2114-5|pages=181\u2013}}</ref>\n\n==References==\n{{Reflist|2}}\n\n{{Neurotransmitters}}\n{{Anticonvulsants}}\n{{GABA receptor modulators}}\n\n{{DEFAULTSORT:Amino-beta-hydroxybutyric acid, gamma-}}\n[[Category:Amino acids]]\n[[Category:Anticonvulsants]]\n[[Category:Beta hydroxy acids]]\n[[Category:GABA analogues]]\n[[Category:GABAA receptor agonists]]\n[[Category:GABAB receptor agonists]]\n[[Category:Human metabolites]]\n[[Category:Neurotransmitters]]\n", "text_old": "{{DISPLAYTITLE:''gamma''-Amino-''beta''-hydroxybutyric acid}}\n{{Drugbox\n| drug_name = \u03b3-Amino-\u03b2-hydroxybutyric acid\n| IUPAC_name = (\u00b1)-4-amino-3-hydroxybutanoic acid\n| image = GABOB.png\n| width = 225px\n| image2 = GABOB3d.png\n| width2 = 150px\n\n<!--Clinical data-->\n| tradename = Gamibetal, others\n| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->\n| pregnancy_US = <!-- A / B / C / D / X -->\n| pregnancy_category = \n| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->\n| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->\n| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->\n| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->\n| legal_status = \n| routes_of_administration =\n\n<!--Pharmacokinetic data-->\n| bioavailability = \n| protein_bound = \n| metabolism = \n| elimination_half-life = \n| excretion =\n\n<!--Identifiers-->\n| CAS_number = 924-49-2\n| CAS_supplemental = <br />352-21-6\n| ATC_prefix = \n| ATC_suffix = \n| PubChem = 2149\n| ChEBI = 16080\n| ChEMBL = 93515\n| ChemSpiderID = 2064\n| DrugBank = \n| synonyms = Buxamine; Buxamina; Bussamina; \u03b3-Amino-\u03b2-hydroxybutyric acid; GABOB; \u03b2-Hydroxy-\u03b3-aminobutyric acid; \u03b2-Hydroxy-GABA\n\n<!--Chemical data-->\n| C=4 | H=9 | N=1 | O=3 \n| molecular_weight = 119.12 g/mol\n| SMILES = C(C(CN)O)C(=O)O\n| StdInChI_Ref = \n| StdInChI = 1S/C4H9NO3/c5-2-3(6)1-4(7)8/h3,6H,1-2,5H2,(H,7,8)\n| StdInChIKey_Ref = \n| StdInChIKey = YQGDEPYYFWUPGO-UHFFFAOYSA-N\n}}\n\n'''\u03b3-Amino-\u03b2-hydroxybutyric acid''' ('''GABOB'''), also known as '''\u03b2-hydroxy-\u03b3-aminobutyric acid''' ('''\u03b2-hydroxy-GABA'''), and sold under the brand name '''Gamibetal''' among others, is an [[anticonvulsant]] which is used for the treatment of [[epilepsy]] in [[Europe]], [[Japan]], and [[Mexico]].<ref name=\"IndexNominum2000\">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA44|date=January 2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=44\u2013}}</ref><ref name=\"Smith2013\">{{cite book|author=Michael Bryant Smith|title=Methods of Non-\u03b1-Amino Acid Synthesis, Second Edition|url=https://books.google.com/books?id=pWxmAQAAQBAJ&pg=PA146|date=23 October 2013|publisher=CRC Press|isbn=978-1-4665-7789-3|pages=146\u2013}}</ref> It is a [[GABA analogue]], or an [[structural analog|analogue]] of the [[neurotransmitter]] [[\u03b3-aminobutyric acid]] (GABA), and has been found to be an [[endogenous]] [[metabolite]] of GABA.<ref name=\"Smith2013\" /><ref name=\"CooperBloom2003\">{{cite book|author1=Jack R. Cooper|author2=Floyd E. Bloom|author3=Robert H. Roth|title=The Biochemical Basis of Neuropharmacology|url=https://books.google.com/books?id=vNaM55VDoF8C&pg=PA112|year=2003|publisher=Oxford University Press|isbn=978-0-19-514007-1|pages=112\u2013}}</ref><ref name=\"MelisPaoletti2014\">{{cite journal|last1=Melis|first1=Gian B.|last2=Paoletti|first2=A. M.|last3=Mais|first3=V.|last4=Mastrapasqua|first4=N. M.|last5=Strigini|first5=F.|last6=Fruzzetti|first6=F.|last7=Guarnieri|first7=G.|last8=Gambacciani|first8=M.|last9=Fioretti|first9=P.|title=Dose-related effects of \u03b3-amino \u03b2-hydroxy butyric acid (GABOB) infusion on growth hormone secretion in normal women|journal=[[Journal of Endocrinological Investigation]]|volume=5|issue=2|year=2014|pages=101\u2013106|issn=0391-4097|doi=10.1007/BF03350499}}</ref><ref name=\"Hayashi1959\">{{cite journal|last1=Hayashi|first1=Takashi|title=The inhibitory action of \u03b2-hydroxy-\u03b3-aminobutyric acid upon the seizure following stimulation of the motor cortex of the dog|journal=The Journal of Physiology|volume=145|issue=3|year=1959|pages=570\u2013578|issn=0022-3751|doi=10.1113/jphysiol.1959.sp006163|pmid=13642322|pmc=1356963}}</ref>\n\n==Medical uses==\nGABOB is an anticonvulsant and is used in the treatment of [[epilepsy]].<ref name=\"IndexNominum2000\" /><ref name=\"Smith2013\" />\n\n==Pharmacology==\nGABOB is a [[GABA receptor agonist]].<ref name=\"Colombo2017\">{{cite book|author=Giancarlo Colombo|title=GABAB Receptor|url=https://books.google.com/books?id=ONHBDQAAQBAJ&pg=PA25|date=17 January 2017|publisher=Springer|isbn=978-3-319-46044-4|pages=25\u2013}}</ref> It has two [[stereoisomer]]s, and shows [[stereoselectivity]] in its actions.<ref name=\"Colombo2017\" /> Specifically, (''R'')-(\u2013)-GABOB is a moderate-[[potency (pharmacology)|potency]] [[agonist]] of the [[GABAB receptor|GABA<sub>B</sub> receptor]], while (''S'')-(+)-GABOB is a [[partial agonist]] of the GABA<sub>B</sub> receptor and an agonist of the [[GABAA receptor|GABA<sub>A</sub> receptor]].<ref name=\"Colombo2017\" /> (''S'')-(+)-GABOB is around twice as potent an anticonvulsant as (''R'')-(\u2013)-GABOB.<ref>{{ cite journal |vauthors=Roberts E, Krause DN, Wong E, Mori A | title = Different Efficacies of d- and l-\u03b3-Amino-\u03b2-Hydroxybutyric Acids in GABA Receptor and Transport Test Systems | journal = Journal of Neuroscience | year = 1981 | volume = 1 | issue = 2 | pages = 132\u2013140 | pmid = 6267220 | pmc = 6564147 | url = http://www.jneurosci.org/content/1/2/132.full.pdf | doi = 10.1523/JNEUROSCI.01-02-00132.1981 }}</ref> GABOB is used medically as a [[racemic mixture]].<ref name=\"Colombo2017\" />\n\nRelative to GABA, GABOB has more potent [[Neurotransmitter#Excitatory and inhibitory|inhibitory]] effects on the [[central nervous system]], perhaps due to its greater capacity to cross the [[blood\u2013brain barrier]].<ref name=\"Hayashi1959\" /><ref name=\"De MaioPasquariello1963\">{{cite journal|last1=De Maio|first1=D.|last2=Pasquariello|first2=G.|title=Gamma-amino-beta-hydroxybutyric acid (GABOB) and brain serotonin|journal=Psychopharmacologia|volume=5|issue=1|year=1963|pages=84\u201386|issn=0033-3158|doi=10.1007/BF00405577|pmid=14085623}}</ref> However, GABOB is of relatively low potency as an anticonvulsant when used by itself, and is more useful as an [[adjuvant]] treatment used alongside another anticonvulsant.<ref>{{ cite journal |vauthors=Chemello R, Giaretta D, Pellegrini A, Testa G |trans-title= Effect of \u03b3-amino-\u03b2-hydroxybutyric acid (GABHB) on experimentally-induced epileptic activity | language = Italian | journal = Rivista di Neurologia | year = 1980 | volume = 50 | issue = 4 | pages = 253\u2013268 | pmid = 7466221 | title=[Effect of gamma-amino-beta-hydroxybutyric acid (GABHB) on experimentally-induced epileptic activity]}}</ref><ref>{{ cite journal |vauthors=Garc\u00eda-Flores E, Far\u00edas R | title = \u03b3-Amino-\u03b2-hydroxybutyric acid as add-on therapy in adult patients with severe focal epilepsy | journal = Stereotactic and Functional Neurosurgery | year = 1997 | volume = 69 | issue = 1\u20134 Pt 2 | pages = 243\u20136| pmid = 9711762 | doi=10.1159/000099882}}</ref>\n\n==Chemistry==\nGABOB, or \u03b2-hydroxy-GABA, is a close [[structural analog]]ue of GABA (see [[GABA analogue]]), as well as of [[\u03b3-hydroxybutyric acid]] (GHB), [[phenibut]] (\u03b2-phenyl-GABA), [[baclofen]] (\u03b2-(4-chlorophenyl)-GABA),<ref name=\"pmid11830761\">{{cite journal | vauthors = Lapin I | title = Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug | journal = CNS Drug Rev | volume = 7 | issue = 4 | pages = 471\u201381 | year = 2001 | pmid = 11830761 | doi = 10.1111/j.1527-3458.2001.tb00211.x| url = | pmc = 6494145 }}</ref> and [[pregabalin]] (\u03b2-isobutyl-GABA).\n\n==Society and culture==\n\n===Generic name===\nGABOB has been referred to by the [[generic term|generic name]] ''buxamine'' or ''buxamina''.<ref name=\"IndexNominum2000\" /><ref name=\"Colombo2017\" />\n\n===Brand names===\nGABOB is sold primarily under the brand name Gamibetal.<ref name=\"IndexNominum2000\" /> It has also been marketed under a variety of other brand names including Aminoxan, Bogil, Diastal, Gabimex, Gabomade, Gaboril, Gamalate, and Kolpo.<ref name=\"IndexNominum2000\" /><ref name=\"Muller1998\">{{cite book|author=Muller|title=European Drug Index: European Drug Registrations, Fourth Edition|url=https://books.google.com/books?id=2HBPHmclMWIC&pg=PA181|date=19 June 1998|publisher=CRC Press|isbn=978-3-7692-2114-5|pages=181\u2013}}</ref>\n\n==References==\n{{Reflist|2}}\n\n{{Neurotransmitters}}\n{{Anticonvulsants}}\n{{GABA receptor modulators}}\n\n{{DEFAULTSORT:Amino-beta-hydroxybutyric acid, gamma-}}\n[[Category:Amino acids]]\n[[Category:Anticonvulsants]]\n[[Category:Beta hydroxy acids]]\n[[Category:GABA analogues]]\n[[Category:GABAA receptor agonists]]\n[[Category:GABAB receptor agonists]]\n[[Category:Human metabolites]]\n[[Category:Neurotransmitters]]\n", "name_user": "Fswitzer4", "label": "safe", "comment": "added FDA UNII to drug box", "url_page": "//en.wikipedia.org/wiki/Gamma-Amino-beta-hydroxybutyric_acid"}
